Welcome to J.W. Childs Associates
J.W. Childs Associates, L.P. is a 27-year-old investment firm based in Boston with a long history of private equity investing, that is today focused on venture capital investments in biotechnology, pharmaceuticals, and health care consumer products. We invest in a variety of ways: direct investments in companies; co-investments alongside external managers; and investments in the funds of investment managers that we regard as partners. We have a longer time horizon with no pre-determined exit date, which distinguishes us from others in the field. We believe this approach provides stability and flexibility to the companies we invest in. In biotechnology and pharmaceuticals, we focus on clinical-stage assets that address important unmet needs in large or growing markets. We are typically Series A or early round investors seeking to build a significant equity stake and play an active role in the development of the company. Areas of interest include neurosciences, oncology, immunology, stem cells, dermatology, and others.
John W. Childs
John W. Childs is the Chairman of J.W. Childs Associates, L.P., a private equity and special situation investment firm founded in 1995, currently focusing on life science, real estate and consumer brands investments. Previously, John was Senior Managing Director of the Thomas H. Lee Company from 1987 to 1995, where he had broad responsibilities for originating, analyzing, negotiating, and managing leveraged buyout transactions, such as Snapple and General Nutrition Company. Prior to that Mr. Childs held various executive positions in the investment area at the Prudential Insurance Company of America, ultimately serving as Senior Managing Director in charge of the Capital Markets Group. He is currently a Director of Realm, LLC, a premium Napa wine company, Biohaven Pharmaceuticals, Pyramid Biosciences, OMAX Health, VeraDermics and Basin Holdings. Prior to their sale, he was Chairman of the Board of Kosta Browne, Sunny Delight and CHG Healthcare Services. John is also on the board of Delta Waterfowl, Waterfowl Research Foundation and the Wild Salmon Center, focusing on wildlife conservation. Mr. Childs has a B.A. from Yale University and a M.B.A. from Columbia University.
Christopher S. Eklund
Mr. Eklund is Managing Director and a Partner at J.W. Childs Associates, a venture capital investment firm focused on biotechnology, pharmaceuticals, healthcare consumer products and selected other areas of interest. Portfolio investments include Biohaven Pharmaceuticals, Garuda Therapeutics, Pyramid Biosciences, VeraDermics Inc. and Omax Health, a nutritional supplements company where he serves as Chairman. Prior to joining J.W. Childs Associates, he was Managing Director and Head of Corporate Strategy at New York Life Investment Management. He has been a director or managing director at Berkshire Capital Corporation, Furman Selz LLC, and Merrill Lynch & Co. Mr. Eklund received an A.B. from Harvard College and an M.B.A. from Harvard Business School. He holds the Chartered Financial Analyst designation and is a member of the New York Society of Securities Analysts.
Thank you for visiting our website.
Contact information is outlined below.
165 Sago Palm Road
Vero Beach, Florida 32963
772 231 7007